Towards the establishment of a consensus real-time qPCR to monitor Trypanosoma cruzi parasitemia in patients with chronic Chagas disease cardiomyopathy: A substudy from the BENEFIT trial
Under a Creative Commons license
open access
Graphical abstract
Establishment of a consensus real-time qPCR to compare Trypanosoma cruzi burden in blood of chronic cardiomyopathy Chagas disease patients from the BENEFIT clinical trial.
Highlights
► We established a SYBR Green real-time qPCR assay to quantify T. cruzi load in blood. ► Chronic Chagas cardiomyopathy patients from the BENEFIT trial were evaluated. ► The median parasitic load found in Brazilian patients was 0.1 parasite equivalents/mL. ► Chronic Chagas disease patients from Colombia and Argentina yielded parasitemia values roughly 20 times higher than patients from Brazil. ► qPCR is useful to detect and quantify low parasite burden in chronic Chagas disease.
Keywords
Cardiac chronic Chagas disease
Molecular diagnosis
Real-time PCR
BENEFIT
Trypanosoma cruzi
Cited by (0)
Copyright © 2012 Elsevier B.V.